and the SEKOIA Study Group
INTRODUCTION
Osteoarthritis (OA) is one of the most widespread musculoskeletal disorders worldwide (1, 2) , and the knee is a commonly affected joint (3) . During natural disease progression, the joint affected will have dramatic structural changes, which lead to increasing levels of pain and disability for the patient.
Although pain is the most commonly reported manifestation of knee OA (4), quantifying structural disease progression is important to aid in understanding the risk factors for OA progression | 301 and to evaluate nonpharmacologic and pharmacologic treatments. In epidemiologic studies of knee OA, monitoring of structural disease progression has conventionally been based on a radiographic definition of knee OA (5) , and knee joint space width (JSW), as a continuous measure, is currently the only Food and Drug Administration-approved end point for clinical trials assessing potential disease-modifying OA drugs (6) . JSW refers to measurement of the minimum medial tibiofemoral interbone distance and is assessed in a standard metric scale of millimeters. Knee JSW measurements are small, and in knees from healthy individuals, maximum values are approximately 8 mm (7). However, it has also been estimated that joint space measurements could be in error by up to 1 mm (8) , making it difficult to distinguish real deterioration in disease from measurement error. Previous studies have shown that both the technique used to read the radiograph and positioning of the knee during the radiograph can have a substantial influence on measured JSW (9, 10) .
To date, no single gold standard statistical method has been recommended in epidemiologic studies that focus on disease progression through monitoring JSW measurements. When JSW measurements have been shown to be normally distributed, OA disease progression has been compared between groups using the simple method of calculating the mean difference between measurements and then testing whether group differences are significant, using such statistical techniques as paired t-tests (11) . Nonparametric rank comparisons have also been used to compare structural change if JSW measurements have a skewed distribution (12) . However, such statistical techniques will only reveal differences in means between groups or indicate whether a population mean joint space has changed over time; such methods give no information on changes within individuals. An individual's change is the observed difference between 2 measurements taken at different times, and this change may be dominated by measurement error in either 1 or both measurements. In addition to obscuring disease deterioration, measurement error may lead to an apparent increase in joint space being observed. Due to the pathologic process associated with OA, i.e., cartilage volume loss, with ultimate involvement of underlying bone, any significant observed increase in JSW could possibly arise as a result of measurement error. Therefore, in both research and clinical settings, minimizing the effect of measurement error is important, to identify differences that are more likely to be due to real change in disease. In research, ensuring that the effects of any treatment or behavioral factors related to disease progression are correctly identified is important. In a clinical setting, identification of rapid radiologic progression may inform clinical management.
The Reliable Change Index (RCI) is a statistical method for identifying whether an observed change within an individual is meaningful in the presence of measurement error (13) . The RCI provides a method of determining whether an individual's observed change is likely to be true or whether the change is attributable to measurement error; the greater the error in the measurement under investigation, the lower the likelihood that an observed change can be attributed to deterioration.
To date, the RCI has been mainly used in health psychology, and little is known about its value outside this setting (14) . We therefore assessed the use of the RCI in a clinical research setting by implementing the index as a novel approach to estimate OA progression. We considered measurements of knee JSW taken at yearly intervals, within the control arm of an international, multicenter, randomized controlled trial of therapy for knee OA. RCI results were compared with crude differences and with the well-recognized cut points of 0.5 mm and 0.8 mm in joint space narrowing (JSN) (15) .
MATERIALS AND METHODS
Study design. This study used data from patients randomized to the placebo arm of the 3-year Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA) (16) . This was an international trial established to assess the effect of a drug treatment, strontium ranelate, on radiologic and clinical progression of OA in the knee joint. Patients were recruited into the trial between 2006 and 2008 from 98 study centers across 18 different countries and were randomized to either a drug regimen of strontium ranelate 1gm/day, strontium ranelate 2 gm/day, or a placebo treatment. Participants were recruited from secondary care establishments where they were already receiving outpatient care for knee OA. To be eligible for entry into SEKOIA, ambulatory white men and women age ≥50 Radiographs were taken at the time of selection and then annually on the target knee, using a standardized technique described elsewhere (19) . The radiographer recorded a fixed-flexion posterioanterior view (fixed angle 10°), using a SynaFlexer positioning frame (BioClinica, formerly Synarc) (20) . All radiographs were measured centrally (at INSERM UMR 1033, Lyon, France) by a single reader (OB or JYR) blinded to treatment allocation and participant identity. Minimal JSW in millimeters at the medial tibiofemoral compartment was measured using a standardized computer-assisted method (21) . Radiologic progressors were defined as patients whose joint space changed by ≥0.5 mm or ≥0.8 mm over the 3-year duration of SEKOIA, as per the definition developed by Bruyere et al in 2005 (15, 16) .
SIGNIFICANCE & INNOVATIONS

RCI.
The RCI was first developed in 1991 by Jacobson and Truax (13) . The principle behind the index is to determine whether the magnitude of change observed in a study participant can be attributed to true change, i.e., the change observed is more than could be explained by the unreliability of the measure. Several variations of the RCI have been proposed (22) , but all variations identify the extent to which study participants' current measurements differ from their previous measurements. All variations of the RCI follow the same fundamental expression:
where Y is the study participant's actual measurement at the latter time point, Yʹ represents the predicted measurement for the study participant at the latter time point of interest, and SE is the standard error of the score. The different approaches to the RCI vary in how they determine the different elements of the RCI. The version that was explored within this study was developed by Christensen and Mendoza (23) . The RCI formula for each study participant, which produced a standardized RCI score, is:
The predicted score is represented by the study participant's measurement at time point 1 (X 1 ) and the same study participant's actual measurement at time point 2 (X 2 ). The SE is derived using S 2 1 and S 2 2 , which are the variances of the measurements at time points 1 and 2, respectively. S 1 and S 2 are the SDs of the measurements at time points 1 and 2, respectively, and r xy is Pearson's correlation coefficient between the mea surements at the 2 time points. Using this version of the RCI does not require the assumption of equal variance in measurements between time points.
The RCI calculation yields a standardized Z score (i.e., the scores have a mean of 0 and an SD of 1). Following the convention of using a 5% level of significance, an RCI score of ±1.96 or greater in magnitude denotes a significant difference, indicating that the change observed reflects more than the fluctuations in the measurement procedure. Each study participant's RCI score can be categorized into 1 of 3 categories: an increase (RCI greater than 1.96), a decrease (RCI less than −1.96), or stable (RCI between −1.96 and 1.96). A magnitude of change thresh- Statistical analysis. Study participants' continuous characteristics were checked for normality and summarized using means ± SDs. Crude differences in JSW were calculated between each SEKOIA study visit to provide a change in JSW in millimeters per year between each study year. The RCI was calculated between each SEKOIA study visit as described above for all study participants. All analyses were undertaken using Stata software, version 13.
RESULTS
In the SEKOIA study, 559 patients were randomized to the placebo arm, with demographic characteristics shown in Table 1 . On entry, participants had a median disease duration of slightly more than 4 years, with men having experienced knee OA longer than women. The majority of the participants (63%) had K/L grade 2 at baseline, and proportions were similar in men and women. The participants' mean ± SD age was 62.8 ± 7.5 years, with the mean for men being greater than that for women, at 63.8 ± 7.8 and 62.3 ± 7.3 years, respectively. The mean ± SD JSW at baseline was 3.51 ± 0.83 mm, which reduced to 3.15 ± 1.00 mm by the end of the study. The minimum JSW at baseline was 0.65 mm, reducing to 0.38 mm during the study, and the largest individual reduction in JSW over the study was 3.34 mm. The 472 intent-to-treat placebo patients were used here to assess change in JSW. Table 2 and  Table 3 show the crude changes and RCI results across all SEKOIA study years.
Of the 465 study participants who had knee JSW measurement at baseline and year 1, nearly 70% had either no change or an apparent decrease in JSW over the year when assessed using crude change, and this figure was nearly 60% between the remaining study years (Table 2 ). An RCI value was calculated for the differences in measurements between each SEKOIA study visit for each study participant. The SD at baseline for all JSW measurements was 0.82, and therefore the variance of JSW measurements at baseline was 0.67, while for all JSW measurements at year 1 the SD was 0.92 and the variance 0.84. The correlation between the 2 time points was 0.84. As an example, for a participant with a baseline JSW of 4.841 mm and a JSW at year 1 of 3.981 mm, the RCI value would be:
Thus the RCI for the study participant indicates that no statistically significant change in JSW has occurred. Performing this calculation for each study participant between baseline and year 1 indicated that 28 participants (6.0%) had an RCI less than −1.96 when assessing the observed difference. Thus, only in these 28 study participants was a statistically reliable decrease in JSW observed that was larger than would be expected through fluctuation in the joint space measurements or through measurement error. A similar pattern was observed between year 1 and year 2, and between year 2 and year 3, with 4.5% and 4.0% of patients, Progression threshold, mm, no.
1.23
* Values are the number (%) unless indicated otherwise. JSN = joint space narrowing.
respectively, having a significant reliable decrease in knee joint space measurements between these years.
Conversely, approximately 30% of study participants were identified as having an increase in crude JSW measurement between baseline and year 1, and approximately 42% of study participants were identified as having a crude increase between year 1 and year 2, or between year 2 and year 3. Using the RCI calculation, 5 study participants (1.1%) had an RCI >1.96 when the observed differences between baseline and year 1 were assessed. These 5 study participants are of note because they appear to have had an increase in JSW greater than can be explained by the fluctuations of an imprecise measurement procedure. Use of the RCI for measurements between year 1 and year 2 and between year 2 and year 3 showed that only 5 participants (1.3%) and 3 participants (0.9%), respectively, had an increase in JSW during those time periods. No study participants consistently had a statistically reliable increase or decrease across all the following time periods: between baseline and year 1, between year 1 and year 2, and between year 2 and year 3.
Of the 336 study participants with measurements at baseline and year 3, 78% had crude decreases in JSW over the 3-year duration, with nearly 36% having a decrease in JSW ≥0.5 mm, and 18.5% having JSN of ≥0.8 mm. This measure of progression also identified a greater number of study participants with a decrease in knee JSW than the 11% identified using the RCI score (Table 3) . When considering those study participants who were identified as having a crude increase in JSW between baseline and year 3 (74 participants) only 1 participant (0.3%) was still identified as having an increase when using the RCI score.
All RCI values were normally distributed, and a magnitude of change in millimeters (threshold) was calculated by transforming the RCI results to give a change in JSW, above which a statistically reliable change occurred. When calculating the magnitude of change in millimeters using the RCI, the magnitude varied between 0.85 mm and 1.23 mm for the different study periods under consideration. Very similar patterns were seen when RCI scores were calculated for men and women, and by K/L grade separately.
DISCUSSION
The aim of this study was to assess the effectiveness of the RCI as a novel approach to estimating OA progression, through assessment of knee JSW at yearly intervals. Although individual disease progression would almost certainly not be classified using the crude difference alone, if the measurements of the crude differences were taken in isolation, they would lead to the conclusion that between baseline and year 1, 70% of those study participants under observation had a worsening of their knee OA. However, use of the RCI indicates that only 6.0% of study participants (24) had a statistically reliable decrease in observed JSW that was larger than would be expected through measurement error in joint space measurements between baseline and year 1. Therefore considerably fewer study participants than initially highlighted through simple differences can reliably be considered to have had a decrease in joint space. Similar patterns were observed between years 1 and 2, and between years 2 and 3. Considerably more study participants, 10.7% (n = 36), had a statistically reliable decrease in observed change in JSW across the total duration of the SEKOIA trial compared to the differences between singular study years, indicating that reliable change becomes easier to detect when longer time periods exist between joint space measurements. This fact may be explained in part by greater time for disease progression to occur, allowing for potentially greater deterioration, which can be more easily distinguished from the measurement error that is still present.
Conversely, approximately 31% of study participants between baseline and year 1, and approximately 42% of study participants between year 1 and year 2, or between year 2 and year 3, were identified as having an absolute increase in JSW. Because real increases are extremely unlikely, this finding shows the impact of measurement error. If crude differences are assessed, without taking any account of measurement error, more than one-third of study participants would appear to have had some improvement in their knee OA condition. Use of the RCI identified a markedly lower number of 5 participants (1.1%) between baseline and year 1, 5 (1.3%) between years 1 and 2, and only 3 (0.9%) between years 2 and 3 as having an increase in JSW.
To date, no studies have been identified that apply the RCI methodology within musculoskeletal research, not only to monitor joint space measurements but also to assess disease deterioration. The RCI has, however, been successfully applied within psychological and neurologic research. For example, Ferguson et al (25) used the RCI to determine clinically significant change between pre-and postintervention Short Form 36 health survey scores that provide a continuous measure of patient health. Ferguson highlighted the fact that the use of the RCI is an important technique, because assessing crude differences alone does not provide reliable information about whether an intervention has had clinically meaningful effects (26) . However, an assumption of the RCI is the stability of measurements between time points, and thus this method has not been previously applied to assess deterioration. The natural disease progression of OA is a slow process, often taking many years. Therefore, the assumption would be that on an annual basis, little or no change in JSW in a study participant would have occurred, and in this novel application of the RCI the assumption of stability was upheld.
There are other statistical techniques and metrics currently used within musculoskeletal research to identify whether change has been significant, such as the standard error of the measurement or the stan dardized response mean. However, neither of these techniques is appropriate for assessment at the individual level rather than the cohort level. Therefore, an advantage of using the RCI is that reliability of an individual study participant's change can be determined, and additionally the estimate of the SE used within the RCI calculation can be used to quantify the JSW change, above which change could be considered statistically reliable. Although the RCI has its merits, there has also been much debate and criticism of the technique (22, 24) . One of the major criticisms is that although all variations of the calculation can be simplified to the same fundamental expression, each approach differs slightly in how the elements of the RCI are calculated. For example, the original definition of the RCI developed by Jacobson and Truax (13) requires an externally derived test-retest reliability coefficient to be able to calculate the SE and assumes equal variance in the measurements at both time points. Hinton-Bayre (22) has made a comparison of the different RCI variations, but there is currently no consensus as to which RCI should be used.
A further criticism of the RCI is that it is specific but not very sensitive, though this fact is partly due to the magnitude of measurement error within longitudinal studies. Within this study, the conventional 5% level of significance was followed, meaning that the cut point for RCI scores was ±1.96, but this cut point is arbitrary, and to increase the sensitivity of the RCI a less strict cutoff could be used.
The RCI aims to distinguish true progression of JSN in those patients with knee OA from measurement error. Although use of JSW longitudinally is the current gold standard for monitoring disease progression, previous studies have shown that inconsistent knee positioning during radiographs can cause a systematic shift in JSW (9) , and so change in JSW may be due to change in positioning of the knee during radiographs rather than disease progression. However, previous studies have shown that the use of the intermargin distance is optimal in reducing variation in JSW due to knee positioning (27) . The minimal JSW in millimeters at the medial tibiofemoral compartment, the intermargin distance, was measured in SEKOIA annually from radiographs obtained under strict study protocol (17, 19) . Therefore, the data in this study were collected with all the associated safeguards around methodology and training, and all radiographs were assessed by 1 reader, reducing measurement error. Thus, the joint space measurements collected during the SEKOIA study probably contain less measurement error than routine clinical measurements. Because there are different radiographic techniques that can be used to obtain knee radiographs, assessing the use of the RCI in data where other methods have been used would be important, particularly in routine clinical practice. However, it is important to remember that the RCI only provides statistically reliable change and does not provide information about the reason for change. The RCI is thus unable to distinguish changes in JSW due to variability in the radiographic positioning from disease progression.
Because there is no gold standard method for assessing significant change in JSW when assessing OA disease progression, there is no comparator for the RCI. However, the use of this novel approach does take account of measurement error, unlike calculation of crude differences. The formula is also simple enough that summary statistics derived from the study population enable assessment of individual study participants' reliable change.
Despite its simplicity, a conceptual problem with the RCI is that no account is taken within the calculation of the duration between the study visits. However, application of the RCI informs of change thresholds that can be used to further explore OA disease progression, particularly in a clinical trial setting. The index can help with determining study duration and assist in sample size determination. In addition, once calculated, the RCI groupings and individual scores might also be used in further statistical analysis to investigate characteristics and phenotypes that may be associated with disease progression, after accounting for the presence of measurement error.
There are some limitations to this study. The study participants already had established OA when recruited into SEKOIA, and assessing the performance of the RCI in a population with wider variability in JSW would be of value. The RCI notably did not remove all apparent increases in JSW. No measure is entirely reliable, and there is always a balance between the sensitivity and specificity of the cut points chosen. To eliminate all apparent increases, a higher level of statistical significance could be used within the RCI calculation, though this practice would reduce the number of decreases identified. Alternatively, if the concern was about missing true deterioration, a lower level could be used.
Few studies have assessed long-term reduction of joint space in a population of patients with OA of the knee. Applying the RCI within knee OA disease progression studies should enable a greater understanding of the progression of JSN. If the value of the RCI is confirmed in other populations, it may aid research, lead to better management of patients with the disease, and assist in improving and/or maintaining the quality of life for a patient with knee OA.
